The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Revenue growth of over 10% was primarily organic, fueled by broad clinical demand across physician, hospital, and consumer channels.

Strategic collaborations with Corewell Health and Fresenius Medical Care contributed 9% to total volume, demonstrating the success of the Co-Lab partnership model.

Revenue per requisition increased by 2.9% (excluding business mix impacts), driven by a higher number of tests per requisition and a shift toward high-value advanced diagnostics.

Management attributed margin pressure to wage increases and investments in Project Nova, partially offset by productivity gains from automation and AI implementations.

The physician channel saw high single-digit growth due to expanded health plan access and increased business with existing customers in prevention and wellness.

Advanced diagnostics in brain health, cardiometabolic, and oncology grew by double digits, reflecting a multi-biomarker approach to chronic disease management.

Operational excellence initiatives remain on track to deliver 3% annual cost savings through the Invigorate program and front-end specimen processing automation.

Full-year 2026 guidance was raised for both revenue and EPS, reflecting strong first-half momentum and sustained demand for lab insights.

The updated outlook assumes operating margin expansion for the full year, despite anticipated headwinds from higher fuel costs and concentrated Project Nova spending in the second half.

Management expects to transition the Corewell Health relationship to a joint venture in early 2027 following the completion of a new lab facility in Michigan.

Guidance includes a 30 basis point revenue headwind from the expiration of ACA exchange subsidies, though current trends show sicker patients are maintaining higher test volumes.

The company plans to roll out the Flatiron Health OncoEMR integration nationwide later this year to simplify cancer test ordering for 4,700 clinicians.

Adjusted EPS included a $0.10 benefit from the favorable resolution of various tax contingencies during the second quarter.

Supplemental deferred compensation plans (SDCP) created a 20 basis point headwind to operating margin due to mark-to-market investment valuations.

Management flagged PAMA reimbursement as a key variable, with potential outcomes ranging from new CMS rates in 2027 to the passage of the RESULTS Act or further legislative delays.

New York State approval for Haystack MRD allows for commercial expansion to all 50 states, though management is pacing investment commensurate with reimbursement milestones.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management noted that while enrollment is down over 20%, revenue remains flattish because healthier individuals dropped off while sicker patients remained, increasing tests per requisition.

The company is maintaining its 30 basis point headwind assumption for the full year as a precautionary measure for the second half.

Management explicitly stated they are seeing no meaningful change in bad debt or deterioration in collection timing from hospitals.

Patient concessions remain stable at approximately 5% of revenues, supported by tight controls and sliding scale payment programs.

Growth is driven by tests per requisition increasing from a pre-COVID range of 3.5-4.0 to north of 4.5 today.

High-value wellness panels in the consumer channel and advanced diagnostics like brain health and autoimmune testing are providing a structural lift to pricing mix.

Management is pacing commercial spend to align with reimbursement coverage, specifically awaiting decisions from MolDx for Medicare Advantage.

The New York State approval is viewed as a significant quality signal due to the state's rigorous clinical criteria.